With the development of direct acting antivirals (DAAs), the outcomes of hepatitis C treatment have been improved. Triple therapy including peginterferon, ribavirin and boceprevir or telaprevir is the current standard of care for genotype 1 infection in United States and Europe. Recently, sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor and simeprevir, a NS3A protease inhibitor were approved by FDA. Overall SVR was 90% with combination therapy of sofosbuvir, peginterferon and ribavirin for 24 weeks. SVR was 80% for genotype 1 infection with the combination therapy of simepervir, peginterferon and ribavirin. Several DAAs with different viral targets are under clinical trials in various combination including interferon-free regimens.